Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 160.18M | $ 194.62M | $ 292.48M | $ 211.65M | $ 294.64M |
| Gross Profit | $ 97.00M | $ 120.47M | $ 269.99M | $ 130.16M | $ 230.68M |
| Operating Income | $ -50.47M | $ -46.26M | $ -80.78M | $ -264.50M | $ -377.83M |
| EBITDA | $ -13.72M | $ -8.27M | $ 3.06M | $ -189.91M | $ -139.83M |
| Net Income | $ -69.41M | $ -51.92M | $ -94.23M | $ -282.02M | $ -384.84M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 51.87M | $ 42.92M | $ 90.47M | $ 149.80M | $ 269.08M |
| Total Assets | $ 220.67M | $ 241.70M | $ 356.05M | $ 529.35M | $ 644.14M |
| Total Debt | $ 188.73M | $ 104.18M | $ 99.78M | $ 136.05M | $ 126.28M |
| Net Debt | $ 136.86M | $ 61.26M | $ 9.32M | $ -13.75M | $ -102.81M |
| Total Liabilities | $ 269.86M | $ 272.29M | $ 350.82M | $ 455.34M | $ 396.52M |
| Stockholders' Equity | $ -49.19M | $ -30.58M | $ 5.23M | $ 74.01M | $ 247.62M |
| Cash Flow | |||||
| Free Cash Flow | $ -40.69M | $ -23.38M | $ -73.27M | $ -253.02M | $ -110.70M |
| Operating Cash Flow | $ -40.66M | $ -23.38M | $ -73.15M | $ -252.97M | $ -110.39M |
| Investing Cash Flow | $ -33.00K | $ 0.00 | $ -114.00K | $ 39.94M | $ -40.00M |
| Financing Cash Flow | $ 49.66M | $ -25.21M | $ 14.60M | $ 133.73M | $ 231.72M |